<DOC>
	<DOCNO>NCT00563901</DOCNO>
	<brief_summary>High blood pressure one common health problem United States . There many medication treat high blood pressure , large variance people respond medication . It believe genetic variation may contribute inconsistent treatment response . This study use genetic analysis determine whether particular gene interact high blood pressure medication modify risk certain cardiovascular disease .</brief_summary>
	<brief_title>Analyzing How Genetics May Affect Response High Blood Pressure Medications</brief_title>
	<detailed_description>High blood pressure affect nearly one three individual Unites States . There many factor cause high blood pressure , include family history genetic trait , kidney disease , stress , diabetes , diet . If leave untreated , high blood pressure increase one 's risk coronary heart disease ( CHD ) , stroke , heart attack , heart failure . While high blood pressure manage medication , people receive medication treatment high blood pressure still variably risk CHD cardiovascular condition . This risk variation may stem vary drug reaction likely due genetics . This study use genetic analysis determine whether particular gene interact high blood pressure medication modify risk certain cardiovascular disease . This continuation study antihypertensive lipid-lowering treatment prevent heart attack trial ( ALLHAT ) , include randomize trial four high blood pressure drug chlorthalidone , amlodipine , lisinopril , doxazosin . Using sample ALLHAT participant , study analyze interaction candidate gene pathway relevance medication ALLHAT study . Researchers examine single DNA building block multiple gene candidate gene pathway determine whether interaction ALLHAT drug modifies risk cardiovascular outcome . Researchers perform genetic analysis 96 genetic marker use structure association test ( SAT ) false discovery rate ( FDR ) method . These method control population stratification multiple testing . Finally , study establish mechanism researcher continue analysis genetic variant examine study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<criteria>Participant ALLHAT study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>CHD</keyword>
	<keyword>Combined CHD</keyword>
	<keyword>Stroke</keyword>
	<keyword>Combined Cardiovascular Disease ( CVD )</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Hospitalized/Fatal Heart Failure</keyword>
	<keyword>Angina</keyword>
	<keyword>Coronary Revascularizations</keyword>
	<keyword>CHD Mortality</keyword>
	<keyword>Lisinopril</keyword>
	<keyword>Chlorthalidone</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Doxazosin</keyword>
</DOC>